Routine RTA confirmation for Q2 FY26 - no securities received for demat

Compliance View source PDF Explain this filing

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.9%Reaction day

₹1835.00

prior close

₹1858.90

announcement price

In-mkt

timing

Nifty Smallcap 250market+1.1%+0.8% vs market

Pharmaceuticals peers, median of 167sector-0.1%+2.1% vs sector

On the reaction day the stock moved 0.8 pts more than Nifty Smallcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.4

15m

+0.2

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.9+1.1+0.8-0.1+2.1

Next day

+1.7+1.5+0.2-0.1+1.8

+1.4+1.5-0.1-0.3+1.6

+0.1+0.3-0.2-1.0+1.0

-0.7+0.4-1.1-0.8+0.1

-3.6-0.8-2.8-2.2-1.4

-3.0-4.1+1.1-4.7+1.7

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Emcure Pharmaceuticals filed a Regulation 74(5) confirmation with BSE and NSE. MUFG Intime India, the company's Registrar and Share Transfer Agent, confirmed that no securities were received for dematerialization during the quarter ended September 30, 2026. This is a standard quarterly compliance filing submitted by the Company Secretary on October 12, 2026.

Likely market impact

No impact on shareholders or stock price; purely routine regulatory compliance.